BOJ keeps interest rates flat, but flags rate hikes on rising inflation, GDP
Sarah Aebersold, Chief Human Resources Officer at BioLife Solutions Inc. (NASDAQ:BLFS), recently sold a portion of her company stock. According to a filing with the Securities and Exchange Commission, Aebersold disposed of 5,771 shares of common stock on April 1, 2025, at a price of $22.66 per share, totaling approximately $130,770. The transaction comes as BioLife’s stock has experienced significant volatility, with InvestingPro data showing a -9.1% decline over the past week, though maintaining a strong 37.3% gain over the past year.
Following this transaction, Aebersold retains 80,094 shares in the company. The sale was conducted under a prearranged trading plan, complying with Rule 10b5-1, to cover tax withholding obligations related to the vesting of restricted stock. According to InvestingPro analysis, BioLife maintains strong financial health with a current ratio of 4.54, indicating robust liquidity. The company appears fairly valued based on InvestingPro’s Fair Value assessment, with 8 additional exclusive ProTips available for subscribers seeking deeper insights into the company’s prospects.
In other recent news, BioLife Solutions announced its financial results for the fourth quarter and full year of 2024, reporting a total revenue of $22.7 million for the fourth quarter, which exceeded analyst estimates. The company posted a net loss of $2.0 million, smaller than the projected loss of $4.4 million. For the full year, BioLife reported $82.3 million in revenue, excluding $37.7 million from discontinued operations, and a net loss of $11.4 million. BioLife’s Cell Processing segment experienced a 7% sequential increase in revenue to $20.3 million for the fourth quarter, marking five consecutive quarters of growth.
H.C. Wainwright raised its price target for BioLife Solutions to $30, citing the company’s strong performance and maintaining a "Buy" rating. Benchmark also reaffirmed a "Buy" rating with a $30 target, highlighting the company’s optimistic financial outlook for 2025. KeyBanc Capital Markets maintained an "Overweight" rating with a $33 price target, expressing confidence in BioLife’s Cell Processing business and new product introductions.
BioLife’s management anticipates 2025 revenue to range between $95.5 million and $99 million, indicating a 16-20% growth over 2024. The company expects Cell Processing revenue to grow 18-21% and forecasts improved operating margins. BioLife’s biopreservation media is now incorporated into 17 approved cell and gene therapies, with potential for eight more approvals or expansions in the next year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.